Effect of a pneumococcal whole cell vaccine on influenza A-induced pneumococcal otitis media in infant mice.

Vaccine

Pneumococcal Research, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Paediatrics, Royal Children's Hospital, The University of Melbourne, Melbourne, Victoria, Australia. Electronic address:

Published: June 2019

AI Article Synopsis

  • The pneumococcus still causes otitis media (OM) even with vaccines available, prompting research on a whole cell vaccine (WCV) in mice.
  • In a study, infant mice immunized with WCV were infected with both pneumococci and influenza A to observe impacts on OM development; results showed WCV did not stop OM but reduced bacterial density in some cases.
  • Specifically, WCV's effectiveness relied on antibodies and CD4 T cells for reducing bacterial levels, but it did not prevent OM in the tested mouse model.

Article Abstract

The pneumococcus remains a common cause of otitis media (OM) despite the widespread introduction of pneumococcal conjugate vaccines. In mice, a pneumococcal whole cell vaccine (WCV) induces serotype-independent protection against pneumococcal colonisation and invasive disease via T17- and antibody-mediated immunity, respectively. We investigated the effect of WCV on influenza A-induced pneumococcal OM in an infant mouse model. C57BL/6 mice were immunised subcutaneously with a single dose of WCV or adjuvant at 6 days of age, infected with pneumococci (EF3030 [serotype 19F] or PMP1106 [16F]) at 12 days of age, and given influenza A virus (A/Udorn/72/307 [H3N2], IAV) at 18 days of age to induce pneumococcal OM. Pneumococcal density in middle ear and nasopharyngeal tissues was determined 6 and 12 days post-virus. Experiments were repeated in antibody (B6.μMT)- and CD4 T-cell-deficient mice to investigate the immune responses involved. A single dose of WCV did not prevent the development of pneumococcal OM, nor accelerate pneumococcal clearance compared with mice receiving adjuvant alone. However, WCV reduced the density of EF3030 in the middle ear at 6 days post-viral infection (p = 0.022), and the density of both isolates in the nasopharynx at 12 days post-viral infection (EF3030, p = 0.035; PMP1106, p = 0.011), compared with adjuvant alone. The reduction in density in the middle ear required antibodies and CD4 T cells: WCV did not reduce EF3030 middle ear density in B6.μMT mice (p = 0.35) nor in wild-type mice given anti-CD4 monoclonal antibody before and after IAV inoculation (p = 0.91); and WCV-immunised CD4 T cell-deficient GK1.5 mice had higher levels of EF3030 in the middle ear than their adjuvant-immunised counterparts (p = 0.044). A single subcutaneous dose of WCV reduced pneumococcal density in the middle ears of co-infected mice in one of two strains tested, but did not prevent OM from occurring in this animal model.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2019.03.013DOI Listing

Publication Analysis

Top Keywords

middle ear
20
dose wcv
12
density middle
12
ef3030 middle
12
pneumococcal
11
mice
9
pneumococcal cell
8
cell vaccine
8
influenza a-induced
8
a-induced pneumococcal
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!